3,156 Shares in Danaher Co. (NYSE:DHR) Bought by VCI Wealth Management LLC

VCI Wealth Management LLC acquired a new position in Danaher Co. (NYSE:DHR) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,156 shares of the conglomerate’s stock, valued at approximately $730,000.

A number of other large investors have also recently bought and sold shares of DHR. Founders Financial Securities LLC bought a new stake in Danaher in the third quarter worth $218,000. GHP Investment Advisors Inc. lifted its position in Danaher by 540.0% during the 3rd quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after acquiring an additional 135 shares during the last quarter. Meridian Wealth Management LLC lifted its position in Danaher by 99.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 3,264 shares of the conglomerate’s stock worth $810,000 after acquiring an additional 1,628 shares during the last quarter. Strategic Blueprint LLC lifted its position in Danaher by 6.0% during the 3rd quarter. Strategic Blueprint LLC now owns 8,446 shares of the conglomerate’s stock worth $2,096,000 after acquiring an additional 480 shares during the last quarter. Finally, Koshinski Asset Management Inc. lifted its position in Danaher by 16.2% during the 3rd quarter. Koshinski Asset Management Inc. now owns 1,118 shares of the conglomerate’s stock worth $277,000 after acquiring an additional 156 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,132 shares of company stock valued at $21,022,795. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE DHR traded down $4.59 on Thursday, reaching $245.82. The company’s stock had a trading volume of 2,943,521 shares, compared to its average volume of 2,786,286. The firm has a market cap of $182.04 billion, a PE ratio of 42.44, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. The business has a 50-day moving average price of $249.00 and a 200 day moving average price of $230.78. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.48%. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.36 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. Citigroup boosted their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays boosted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Robert W. Baird upped their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, TD Cowen upped their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $270.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.